SCHEMBL6992740

SCHEMBL6992740

CCOC(=O)CN1CCC(N)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.44
PKM P14618 1/20 0.42
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GNAI3 P08754 2/20 0.40
GNAO1 P09471 2/20 0.40
GNAI1 P63096 2/20 0.40
GSK3B P49841 2/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GSK3A P49840 1/20 0.40
HSD11B1 P28845 1/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
MAPT P10636 1/20 0.39
ELANE P08246 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7581129 0.98 SMYD3 (0.43) SMYD3PKMGAASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL21069720 0.98 SMYD3 (0.43) SMYD3PKMGAASMN1; SMN2KDM4E
SCHEMBL18551139 0.91 CHRM1 (0.49) SMYD3PKMGAASMN1; SMN2KDM4E
SCHEMBL13110280 0.90 HSD11B1 (0.40) SMYD3PKMGAASMN1; SMN2KDM4E
SCHEMBL3447796 0.90 HSD11B1 (0.40) SMYD3PKMGAASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL3447798 0.88 HSD11B1 (0.40) SMYD3PKMGAASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL3447794 0.88 HSD11B1 (0.40) SMYD3PKMGAASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL7585696 0.85 GNAI3 (0.44) PKMSMN1; SMN2KDM4EALDH1A1GNAI3
SCHEMBL26986912 0.84 GSK3B (0.41) PKMGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL6642453 0.84 TDP1 (0.41) PKMGAASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236122-B2 Triterpene amine derivatives DFH THERAPEUTICS (US) 2022-02-01 US disclosed
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2021-08-19 US disclosed
WO-2019118612-A1 TARGETING COMPOUNDS ZAFGEN, INC. (US) 2019-06-20 WO disclosed
WO-2019118612-A1 TARGETING COMPOUNDS ZAFGEN, INC. (US) 2019-06-20 WO disclosed
US-9078909-B2 Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-14 US disclosed
US-20130316981-A1 TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-28 US disclosed
US-20100234361-A1 SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-16 US disclosed
WO-2007020261-A2 SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-22 WO disclosed
EP-0750618-B1 OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM UPJOHN CO (US) 2003-02-19 EP disclosed
US-5668286-A ANTIBIOTIC PHARMACIA & UPJOHN COMPANY (US) 1997-09-16 US disclosed
EP-0750618-A1 OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PHARMACIA & UPJOHN COMPANY (US) 1997-01-02 EP disclosed
WO-1995025106-A1 OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PHARMACIA & UPJOHN COMPANY (US) 1995-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES BET1, PGGT1B, NFATC1 SMYD3 2692/4885PKM 4594/4885GAA 1978/4885
US-20130316981-A1 TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, KCNN3 SMYD3 1613/4885PKM 638/4885GAA 908/4885
US-11236122-B2 Triterpene amine derivatives BET1, PGGT1B, NFATC1 SMYD3 2692/4885PKM 4594/4885GAA 1978/4885
US-20100234361-A1 SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, CALCA SMYD3 4298/4885PKM 1967/4885GAA 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.